secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001566044-25-000007
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing
---------------------------------------------------------------------

- Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.
- Cash, cash equivalents and marketable securities $32.7M as of Sep 30, 2025; runway into first half 2027.
- FDA partial clinical hold on VYN202 for male subjects; 12-week dog tox study ongoing to resolve.
- Phase 2b repibresib gel for vitiligo failed primary endpoint F-VASI50; trial being terminated.
- Board initiated strategic review in Aug 2025; evaluating partnerships, M&A, asset sales; LifeSci Capital engaged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000156604425000007/0001566044-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000156604425000007/mnlo-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001566044-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer